Brookline Capital Management Forecasts QNCX FY2028 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Equities research analysts at Brookline Capital Management lowered their FY2028 earnings estimates for shares of Quince Therapeutics in a report released on Thursday, November 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings of $0.11 per share for the year, down from their prior estimate of $0.15. The consensus estimate for Quince Therapeutics’ current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics’ FY2029 earnings at $0.50 EPS.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05).

Other analysts have also recently issued reports about the company. JMP Securities dropped their price target on Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 12th. Citizens Jmp assumed coverage on Quince Therapeutics in a research note on Tuesday, August 5th. They set a “strong-buy” rating and a $9.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Quince Therapeutics in a research note on Wednesday, October 8th. Citigroup began coverage on Quince Therapeutics in a report on Tuesday, August 5th. They set an “outperform” rating for the company. Finally, Zacks Research upgraded shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.

Quince Therapeutics Stock Performance

Shares of QNCX opened at $1.68 on Monday. The stock has a market cap of $93.54 million, a PE ratio of -1.39 and a beta of 1.07. Quince Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $2.45. The firm’s 50-day simple moving average is $1.71 and its two-hundred day simple moving average is $1.53.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in shares of Quince Therapeutics during the second quarter valued at $4,172,000. Ieq Capital LLC bought a new stake in Quince Therapeutics in the 1st quarter worth about $1,073,000. ADAR1 Capital Management LLC raised its position in Quince Therapeutics by 442.1% in the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock worth $1,263,000 after buying an additional 632,076 shares during the last quarter. Vanguard Group Inc. raised its position in Quince Therapeutics by 21.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock worth $2,874,000 after buying an additional 309,349 shares during the last quarter. Finally, Rockefeller Capital Management L.P. bought a new position in Quince Therapeutics during the 2nd quarter valued at about $280,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.